SCHEMBL1020707

SCHEMBL1020707

COc1cccc(Cc2nsc(N(C)CCN(C)S(=O)(=O)c3cccs3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39
SQLE Q14534 2/20 0.39
LMNA P02545 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GBA1 P04062 1/20 0.39
PKM P14618 1/20 0.38
HTR6 P50406 2/20 0.37
POLB P06746 1/20 0.37
NPC1 O15118 1/20 0.36
MEN1 O00255 1/20 0.36
TNF P01375 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
NOD2 Q9HC29 1/20 0.36
NOD1 Q9Y239 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1018717 0.90 RAB9A (0.44) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1020110 0.88 POLB (0.40) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1020632 0.87 NPC1 (0.39) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1021047 0.86 SMN1; SMN2 (0.43) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1020526 0.86 BMP1 (0.41) MAPTL3MBTL1SMN1; SMN2ALDH1A1LMNA
SCHEMBL1020547 0.86 PKM (0.51) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1021213 0.84 MAPT (0.46) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1020403 0.83 GBA1 (0.43) MAPTSMN1; SMN2RAB9AALDH1A1HPGD
SCHEMBL1020588 0.82 NPC1 (0.41) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1
SCHEMBL1019771 0.82 NPC1 (0.41) MAPTL3MBTL1SMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP MAPT 4/4885L3MBTL1 1449/4885SMN1; SMN2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.